Leo Pharma's revenue at standstill – research investments still flush out
Investment in new biological dermatology products has cost Danish Leo Pharma large sums, and acquisitions and sales of established products brought the revenue to a stand-still in 2018. The company anticipates progress this year.
2018 was an eventful year for Danish dermatology group Leo Pharma. The company sold 10 products to Swedish Karo Pharma and acquired Bayer's dematology portfolio. But despite the changes, the revenue is more or less stagnated.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma-researchers receive innovation award
For abonnenter
The Leo Foundation to provide larger research grants
For abonnenter
